Key facts
- This page summarizes Michael G. King Jr.'s Form 4 filing for SAB Biotherapeutics, Inc. (SABS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 30 Nov 2023, 17:00.
Michael G. King Jr. - 30 Nov 2023 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)
- Reporting relationship
- CHIEF FINANCIAL OFFICER
- Issuer ticker
- SABS
- Reported as of
- 30 Nov 2023
- Net transaction value
- +$4,500
- SEC form
- 4
- Accepted by SEC
- 30 Nov 2023, 17:00:07 UTC
- Prior SEC filing
- 03 Nov 2023
- Next SEC filing
- 23 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael G. King, Jr.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael G. King Jr. filed Form 4 for SAB Biotherapeutics, Inc. (SABS) on 30 Nov 2023.
Change
- Previous filing in this sequence was filed on 03 Nov 2023.
- Current net transaction value: +$4,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SABS
transaction
Common Stock
Purchase
- Transaction value
- $4,500
- Shares
- +5,000
- Change %
- Price
- $0.9000
- Shares after
- 5,000
- Date
- 30 Nov 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents 5,000 shares of the Issuer's common stock, par value $0.0001 per share, acquired by the reporting person in an open market transaction.